BioHealth Innovation, Inc. (BHI), a public-private partnership and innovation intermediary is seeking an energetic and motivated life science professional for the role of an Entrepreneur-In-Residence (EIR) with product development experience and subject matter expertise in the fields of neurology and neuroscience. The EIR will reside within the National Institutes of Health (NIH) and will also support intramural and extramural initiatives on an as needed basis.
The EIR program was established at BioHealth Innovation to:
- Retain and bring entrepreneurial talent to the Maryland ecosystem
- Connect resources including institutions, technology assets, people and capital within Maryland that include federal institutions, labs, academic institutions, small businesses, disease foundations and the investor community
- Build/support sustainable life science startups that will add value within the healthcare system and also build upon the existing infrastructure
The EIR will work with BHI leadership to ensure that the activities and outcomes are aligned with BHIs strategic focus.
Moving to advance its leadership in developing vaccines for important public health and biodefense needs, Vaxin Inc. today announced that it has entered into a definitive agreement to acquire Immune Targeting Systems (ITS) Ltd. Vaxin is a clinical stage vaccine development company headquartered in Gaithersburg, Maryland. ITS develops novel T-cell vaccines at its operations in the United Kingdom and France. The deal is an all-stock transaction and is subject to customary closing conditions. The combined company will be known as Vaxin Inc.
MedImmune, the global biologics research and development arm of AstraZeneca, announced today that it has joined the National Institutes of Health (NIH) Centers for Accelerated Innovations (NCAI) program as the first biotech/pharmaceutical company corporate partner.
The NCAI program was launched in September 2013 to improve how basic science advances and discoveries are translated into commercially viable treatments for patients. The National Heart, Lung, and Blood Institute (NHLBI) will provide $32.5 million in grants to establish three translational research Centers of Innovation in Boston, Cleveland and California, consisting of 14 top-tier research institutions. The program seeks to accelerate the commercialization of university-based technologies, and public private partnerships are critical to the success of the NCAI program.
Johns Hopkins University launched its Fast Forward business accelerator two years ago as a way to support the growth of its own entrepreneurial community, but also to help stimulate the Baltimore economy. It recently opened a second accelerator space on the East Side of Baltimore by its medical campus. It’s designed to equip life science startups with the kind of wet lab space that tends to come at a premium and is often too costly for early stage companies with an uncertain future.
MedImmune, the global biologics research and development arm of AstraZeneca, and the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) today announced the signing of a five-year agreement to jointly support research that will help advance drug discovery and manufacturing. The effort will focus on tools and measurements that will be used in the development and production of biopharmaceuticals, which are drugs and treatments derived from biological, rather than chemical, sources.
Roche and Qualcomm have entered into a new collaboration to improve remote monitoring and management of chronic disease patients.
The new deal between the Swiss cancer drug firm and the communication technology specialist will see Roche use Qualcomm Life's 2net Platform to capture data from a patient's medical devices, beginning with anticoagulation metres, and transmit it to Roche's cloud-based services.
Pharma Major Lupin Limited (Lupin) and Celon Pharma S.A. (Celon) announced that they have entered into a definitive agreement under which the companies will jointly develop a fluticasone/salmeterol dry powder inhaler (DPI) product which is a generic version of GlaxoSmithKline's Advair Diskus. Lupin will be responsible for commercialization of the product. Celon will supply the product to Lupin for its commercialization in the United States, Canada, Mexico, and other key markets. GlaxoSmithKline's Advair Diskus® had global sales of over USD 7 billion as of last fiscal.
Crystal City-based Disruption Corp. is partnering with Maryland-based Greenspring Associates, a $3 billion fund of funds that backs some venture capital firms that actively invest in the region, including New Enterprise Associates, Revolution Growth and True Ventures.
Ashton Newhall, co-founder of Greenspring Associates, told me he believes Disruption and Greenspring are "philosophically aligned" on the possibilities of using data analytics to make sounder investments in startups and the private market broadly.
Enterprise Therapeutics Ltd, a drug discovery company focused on new therapeutics for respiratory diseases, today announced that it has secured £1.6m ($2.4m) in initial Series-A financing from Epidarex Capital. The proceeds will fund, in parallel, low molecular weight drug discovery and new target identification programs. The company will be based at the University of Sussex.
Deloitte has launched the 2015 Top Technology Talent Competition for a fifth year seeking innovative ideas from college students on how technology can solve a business problem.
The winner of the 2015 Top Technology Talent Competition will win a trip to one of the Deloitte digital studios in the US, in addition to a six-week summer internship in Deloitte Ireland which will enable them to further develop their idea if they so choose.
Many cancer patients and their families are happy to never look back once they’re safely on the other side of treatment, in remission or cured. But for David Austin and his wife, Emily, whose 6-year-old son now has a clean bill of health, winning the cancer battle was just the first step on another journey to help other cancer patients, particularly those whose treatment involves central lines — catheters placed directly into a vein in the chest to administer chemotherapy or take blood for frequent tests.
It was easy to get my head around the biotech buzz and the digital health marketing blitz that happened last month at the JP Morgan Healthcare Conference.
But here’s the question I heard most often (and gave me the most food for thought): “Can I meet more angels?”
The venture boom that funneled billions of dollars into life sciences companies last year included a big surge in first-time deals, according to a fresh analysis of the numbers for 2014. And the boom in venture investing looks set to continue well into 2015, according to the analysts at PricewaterhouseCoopers and the National Venture Capital Association, working with data provided by Thomson Reuters to put out the MoneyTree report.
At The MidAmerica Healthcare Venture Forum hosted at Chicago’s Fairmont Hotel on March 10 and 11, Healthbox’s Maria Siambekos will host a session about the growing role of healthcare accelerators. Do investors invest in them?
Wednesday, February 25, 2015, 10:00am - 04:00pm
The SBIR/STTR programs promote small business innovation in companies just like yours. The government has research and development needs. Every year, small businesses receive millions of dollars in SBIR/STTR funds for research, development, and commercialization purposes. Spend February 25 hearing from SBIR/STTR program experts.
An overview of the program will provide a comprehensive understanding of SBIR/STTR.
Discover the government's on-going interest in innovation.
Listen to agency experts speak to agency-specific needs and program nuances.
Join us as this amazing gathering of speakers share stories of great successes, near-misses, and the review process. Our speakers embrace questions and will provide answers and direct attendees to information and resources. A box lunch will be provided. Please alert us to any dietary needs in the comments section upon registration.
